Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucosidase, beta, acid | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | fk506-binding protein, putative | 0.0248 | 0.4087 | 0.4087 |
Onchocerca volvulus | Glucosylceramidase homolog | 0.0205 | 0 | 0.5 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, FKBP-type , putative | 0.0248 | 0.4087 | 0.5 |
Echinococcus multilocularis | fk506 binding protein | 0.0248 | 0.4087 | 1 |
Schistosoma mansoni | immunophilin | 0.0248 | 0.4087 | 1 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.0248 | 0.4087 | 0.4087 |
Mycobacterium ulcerans | FK-506 binding protein, peptidyl-prolyl cis-trans isomerase | 0.0248 | 0.4087 | 0.5 |
Plasmodium falciparum | peptidyl-prolyl cis-trans isomerase FKBP35 | 0.0248 | 0.4087 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0216 | 0.1027 | 0.1027 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP4 | 0.0248 | 0.4087 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0216 | 0.1027 | 0.1027 |
Schistosoma mansoni | immunophilin | 0.0248 | 0.4087 | 1 |
Leishmania major | fk506-binding protein 1-like protein | 0.0248 | 0.4087 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Giardia lamblia | FKBP-type peptidyl-prolyl cis-trans isomerase | 0.0248 | 0.4087 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Trichomonas vaginalis | immunophilin, putative | 0.0248 | 0.4087 | 0.4087 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Trypanosoma cruzi | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0248 | 0.4087 | 0.5 |
Loa Loa (eye worm) | FKBP-type peptidyl-prolyl cis-trans isomerase-12 | 0.0248 | 0.4087 | 0.3503 |
Entamoeba histolytica | peptidyl-prolyl cis-trans isomerase, FKBP-type, putative | 0.0248 | 0.4087 | 0.5 |
Trypanosoma brucei | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0248 | 0.4087 | 0.5 |
Echinococcus granulosus | peptidyl prolyl cis trans isomerase FKBP1A | 0.0248 | 0.4087 | 1 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase, putative | 0.0248 | 0.4087 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0312 | 1 | 1 |
Trypanosoma brucei | peptidyl-prolyl cis-trans isomerase, putative | 0.0248 | 0.4087 | 0.5 |
Treponema pallidum | peptidyl-prolyl cis-trans isomerase, FKBP-type, 22 kDa (fklB) | 0.0248 | 0.4087 | 0.5 |
Trichomonas vaginalis | peptidylprolyl isomerase, putative | 0.0248 | 0.4087 | 0.4087 |
Loa Loa (eye worm) | FKBP5 protein | 0.0248 | 0.4087 | 0.3503 |
Leishmania major | peptidylprolyl isomerase-like protein | 0.0248 | 0.4087 | 0.5 |
Echinococcus multilocularis | peptidyl prolyl cis trans isomerase FKBP4 | 0.0248 | 0.4087 | 1 |
Plasmodium vivax | 70 kDa peptidylprolyl isomerase, putative | 0.0248 | 0.4087 | 0.5 |
Trypanosoma cruzi | FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative | 0.0248 | 0.4087 | 0.5 |
Schistosoma mansoni | immunophilin FK506 binding protein FKBP12 | 0.0248 | 0.4087 | 1 |
Giardia lamblia | 70 kDa peptidylprolyl isomerase, putative | 0.0248 | 0.4087 | 0.5 |
Loa Loa (eye worm) | O-glycosyl hydrolase family 30 protein | 0.0312 | 1 | 1 |
Trypanosoma cruzi | peptidyl-prolyl cis-trans isomerase, putative | 0.0248 | 0.4087 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.2213 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845] | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 25.9185 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.